Formosa Pharmaceuticals, founded in 2010, is a clinical-stage biopharmaceutical company with a strong focus on ophthalmology, oncology, and anti-infectives. Striving for excellence in these therapeutic areas, Formosa Pharmaceuticals acquired Activus Pharmaceuticals in 2017, gaining access to a proprietary nanoparticle technology platform (APNT) and two late-stage preclinical assets in ophthalmology. One of their promising ophthalmology candidates, APP13007, has already been submitted for NDA (New Drug Application) to the US FDA for inflammation and pain after ocular surgery.

In collaboration with global strategic partners, Formosa Pharmaceuticals has built an impressive pipeline of diverse assets, each with its own unique advantage and risk profile. Their resources, infrastructure, and network enable them to effectively develop and bring these products to market. Committed to expanding their pipeline and platform technologies, Formosa Pharmaceuticals actively seeks valuable partnerships.

They aim to revolutionize the healthcare industry and make significant contributions to the well-being of patients worldwide. For more information, contact Formosa Pharmaceuticals at +886-2-2755-7659 or visit their website